Survival from breast cancer in women with a BRCA2 mutation by treatment
Open Access
- 18 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 124 (9), 1524-1532
- https://doi.org/10.1038/s41416-020-01164-1
Abstract
Background The impact of various breast-cancer treatments on patients with a BRCA2 mutation has not been studied. We sought to estimate the impact of bilateral oophorectomy and other treatments on breast cancer-specific survival among patients with a germline BRCA2 mutation. Methods We identified 664 women with stage I–III breast cancer and a BRCA2 mutation by combining five different datasets (retrospective and prospective). Subjects were followed for 7.2 years from diagnosis to death from breast cancer. Tumour characteristics and cancer treatments were patient-reported and derived from medical records. Predictors of survival were determined using Cox proportional hazard models, adjusted for other treatments and for prognostic features. Results The 10-year breast-cancer survival for ER-positive patients was 78.9% and for ER-negative patients was 82.3% (adjusted HR = 1.23 (95% CI, 0.62–2.45, p = 0.55)). The 10-year breast-cancer survival for women who had a bilateral oophorectomy was 89.1% and for women who did not have an oophorectomy was 59.0% (adjusted HR = 0.45; 95% CI, 0.28–0.72, p = 0.001). The adjusted hazard ratio for chemotherapy was 0.83 (95% CI, 0.65–1.53: p = 0.56). Conclusions For women with breast cancer and a germline BRCA2 mutation, positive ER status does not predict superior survival. Oophorectomy is associated with a reduced risk of death from breast cancer and should be considered in the treatment plan.Keywords
This publication has 17 references indexed in Scilit:
- The spectrum of mutations predisposing to familial breast cancer in PolandInternational Journal of Cancer, 2019
- Mortality after breast cancer as a function of time since diagnosis by estrogen receptor status and age at diagnosisInternational Journal of Cancer, 2019
- Oestrogen receptor status and survival in women with BRCA2-associated breast cancerBritish Journal of Cancer, 2019
- Predictors of survival for breast cancer patients with a BRCA1 mutationBreast Cancer Research and Treatment, 2017
- Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriersBritish Journal of Cancer, 2016
- Effect of Oophorectomy on Survival After Breast Cancer inBRCA1andBRCA2Mutation CarriersJAMA Oncology, 2015
- Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysisBMJ, 2014
- Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant ChemotherapyJournal of Clinical Oncology, 2010
- Prophylactic oophorectomy in premenopausal women and long-term healthMenopause International, 2008
- Analysis of cancer risk and BRCA1 and BRCA2mutation prevalence in the kConFab familial breast cancer resourceBreast Cancer Research, 2006